Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 45.04% ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

ContentsUS exits Paris Agreement againAre biofuels subsidies at risk?Buffer factors: Republicans could ringfence biofuelsWhy ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

There is a need for nuanced immigration policies that emphasise the complementary relationship between foreign talent and ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

Experts in every field of medical research gather at meetings to decide which topics and projects are most deserving of funds ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Just after market close on Monday, 89bio divulged that it intends to raise as much as $287.5 million from a secondary stock issue. It will do so in an underwritten public offering of $250 million ...